APO Research
Talk to an analyst

APO RESEARCH · REPORT

General Anaesthetic Medication

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global General Anaesthetic Medication Market Outlook and Growth Opportunities 2026

22 December 2025194 pages

Choose your research edition.

Industry ResearchGeneral Anaesthetic Medication Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal General Anaesthetic Medication Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal General Anaesthetic Medication Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal General Anaesthetic Medication Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal General Anaesthetic Medication Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global General Anaesthetic Medication market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for General Anaesthetic Medication is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for General Anaesthetic Medication is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for General Anaesthetic Medication is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the General Anaesthetic Medication market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the General Anaesthetic Medication market include Aspen Pharma, Hikma Pharmaceuticals, Maruishi, Piramal, AbbVie, Baxter Healthcare, B.Braun, Fresenius-Kabi and Hengrui, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global General Anaesthetic Medication market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of General Anaesthetic Medication and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents General Anaesthetic Medication revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global General Anaesthetic Medication market.

General Anaesthetic Medication Segment by Company

Aspen Pharma

Hikma Pharmaceuticals

Maruishi

Piramal

AbbVie

Baxter Healthcare

B.Braun

Fresenius-Kabi

Hengrui

Nhwa

Xi'an Libang

Yichang Humanwell

General Anaesthetic Medication Segment by Type

Isoflurane

Etomidate

Remifentanil

Sevoflurane

Propofol

Other

General Anaesthetic Medication Segment by Application

Intravenous Anesthetics

Inhalational Anesthetics

General Anaesthetic Medication Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global General Anaesthetic Medication status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the General Anaesthetic Medication key companies, revenue, market share, and recent developments.

3. To split the General Anaesthetic Medication breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions General Anaesthetic Medication market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify General Anaesthetic Medication significant trends, drivers, influence factors in global and regions.

6. To analyze General Anaesthetic Medication competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global General Anaesthetic Medication market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of General Anaesthetic Medication and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of General Anaesthetic Medication.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global General Anaesthetic Medication industry.

Chapter 3: Detailed analysis of General Anaesthetic Medication company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of General Anaesthetic Medication in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of General Anaesthetic Medication in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. General Anaesthetic Medication Industry Trends Table 2. General Anaesthetic Medication Industry Drivers Table 3. General Anaesthetic Medication Industry Opportunities and Challenges Table 4. General Anaesthetic Medication Industry Restraints Table 5. Global General Anaesthetic Medication Revenue by Company (US$ Million) & (2021-2026) Table 6. Global General Anaesthetic Medication Revenue Share by Company (2021-2026) Table 7. Global General Anaesthetic Medication Company Ranking, (2024-2026) & (US$ Million) Table 8. Global General Anaesthetic Medication Key Company Manufacturing Base & Headquarters Table 9. Global General Anaesthetic Medication Company, Product Type & Application Table 10. Global General Anaesthetic Medication Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global General Anaesthetic Medication by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Isoflurane Table 15. Significant Companies of Etomidate Table 16. Significant Companies of Remifentanil Table 17. Significant Companies of Sevoflurane Table 18. Significant Companies of Propofol Table 19. Significant Companies of Other Table 20. Global General Anaesthetic Medication Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 21. Global General Anaesthetic Medication Sales Value by Type (2021-2026) & (US$ Million) Table 22. Global General Anaesthetic Medication Sales Value by Type (2027-2032) & (US$ Million) Table 23. Global General Anaesthetic Medication Sales Value Share by Type (2021-2026) Table 24. Global General Anaesthetic Medication Sales Value Share by Type (2027-2032) Table 25. Significant Companies of Intravenous Anesthetics Table 26. Significant Companies of Inhalational Anesthetics Table 27. Global General Anaesthetic Medication Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global General Anaesthetic Medication Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global General Anaesthetic Medication Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global General Anaesthetic Medication Sales Value Share by Application (2021-2026) Table 31. Global General Anaesthetic Medication Sales Value Share by Application (2027-2032) Table 32. Global General Anaesthetic Medication Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global General Anaesthetic Medication Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global General Anaesthetic Medication Sales Value Share by Region (2021-2026) Table 35. Global General Anaesthetic Medication Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global General Anaesthetic Medication Sales Value Share by Region (2027-2032) Table 37. Global General Anaesthetic Medication Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global General Anaesthetic Medication Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global General Anaesthetic Medication Sales Value Market Share by Country (2021-2026) Table 40. Global General Anaesthetic Medication Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global General Anaesthetic Medication Sales Value Market Share by Country (2027-2032) Table 42. Aspen Pharma Company Information Table 43. Aspen Pharma Business Overview Table 44. Aspen Pharma General Anaesthetic Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Aspen Pharma General Anaesthetic Medication Product Portfolio Table 46. Aspen Pharma Recent Development Table 47. Hikma Pharmaceuticals Company Information Table 48. Hikma Pharmaceuticals Business Overview Table 49. Hikma Pharmaceuticals General Anaesthetic Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Hikma Pharmaceuticals General Anaesthetic Medication Product Portfolio Table 51. Hikma Pharmaceuticals Recent Development Table 52. Maruishi Company Information Table 53. Maruishi Business Overview Table 54. Maruishi General Anaesthetic Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Maruishi General Anaesthetic Medication Product Portfolio Table 56. Maruishi Recent Development Table 57. Piramal Company Information Table 58. Piramal Business Overview Table 59. Piramal General Anaesthetic Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Piramal General Anaesthetic Medication Product Portfolio Table 61. Piramal Recent Development Table 62. AbbVie Company Information Table 63. AbbVie Business Overview Table 64. AbbVie General Anaesthetic Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. AbbVie General Anaesthetic Medication Product Portfolio Table 66. AbbVie Recent Development Table 67. Baxter Healthcare Company Information Table 68. Baxter Healthcare Business Overview Table 69. Baxter Healthcare General Anaesthetic Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Baxter Healthcare General Anaesthetic Medication Product Portfolio Table 71. Baxter Healthcare Recent Development Table 72. B.Braun Company Information Table 73. B.Braun Business Overview Table 74. B.Braun General Anaesthetic Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. B.Braun General Anaesthetic Medication Product Portfolio Table 76. B.Braun Recent Development Table 77. Fresenius-Kabi Company Information Table 78. Fresenius-Kabi Business Overview Table 79. Fresenius-Kabi General Anaesthetic Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Fresenius-Kabi General Anaesthetic Medication Product Portfolio Table 81. Fresenius-Kabi Recent Development Table 82. Hengrui Company Information Table 83. Hengrui Business Overview Table 84. Hengrui General Anaesthetic Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Hengrui General Anaesthetic Medication Product Portfolio Table 86. Hengrui Recent Development Table 87. Nhwa Company Information Table 88. Nhwa Business Overview Table 89. Nhwa General Anaesthetic Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Nhwa General Anaesthetic Medication Product Portfolio Table 91. Nhwa Recent Development Table 92. Xi'an Libang Company Information Table 93. Xi'an Libang Business Overview Table 94. Xi'an Libang General Anaesthetic Medication Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Xi'an Libang General Anaesthetic Medication Product Portfolio Table 96. Xi'an Libang Recent Development Table 97. Yichang Humanwell Company Information Table 98. Yichang Humanwell Business Overview Table 99. Yichang Humanwell General Anaesthetic Medication Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. Yichang Humanwell General Anaesthetic Medication Product Portfolio Table 101. Yichang Humanwell Recent Development Table 102. Research Programs/Design for This Report Table 103. Authors List of This Report Table 104. Secondary Sources Table 105. Primary Sources List of Figures Figure 1. General Anaesthetic Medication Product Image Figure 2. Global General Anaesthetic Medication Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global General Anaesthetic Medication Market Size (2021-2032) & (US$ Million) Figure 4. Global General Anaesthetic Medication Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Isoflurane Image Figure 8. Etomidate Image Figure 9. Remifentanil Image Figure 10. Sevoflurane Image Figure 11. Propofol Image Figure 12. Other Image Figure 13. Global General Anaesthetic Medication Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 14. Global General Anaesthetic Medication Sales Value Share 2021 VS 2025 VS 2032 Figure 15. Global General Anaesthetic Medication Sales Value Share by Type (2021-2032) Figure 16. Intravenous Anesthetics Image Figure 17. Inhalational Anesthetics Image Figure 18. Global General Anaesthetic Medication Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global General Anaesthetic Medication Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global General Anaesthetic Medication Sales Value Share by Application (2021-2032) Figure 21. Global General Anaesthetic Medication Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global General Anaesthetic Medication Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America General Anaesthetic Medication Sales Value (2021-2032) & (US$ Million) Figure 24. North America General Anaesthetic Medication Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe General Anaesthetic Medication Sales Value (2021-2032) & (US$ Million) Figure 26. Europe General Anaesthetic Medication Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific General Anaesthetic Medication Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific General Anaesthetic Medication Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America General Anaesthetic Medication Sales Value (2021-2032) & (US$ Million) Figure 30. South America General Anaesthetic Medication Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa General Anaesthetic Medication Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa General Anaesthetic Medication Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA General Anaesthetic Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada General Anaesthetic Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico General Anaesthetic Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany General Anaesthetic Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France General Anaesthetic Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. General Anaesthetic Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy General Anaesthetic Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain General Anaesthetic Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia General Anaesthetic Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands General Anaesthetic Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries General Anaesthetic Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China General Anaesthetic Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan General Anaesthetic Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea General Anaesthetic Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India General Anaesthetic Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia General Anaesthetic Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia General Anaesthetic Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil General Anaesthetic Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina General Anaesthetic Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile General Anaesthetic Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia General Anaesthetic Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru General Anaesthetic Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia General Anaesthetic Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel General Anaesthetic Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE General Anaesthetic Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey General Anaesthetic Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran General Anaesthetic Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt General Anaesthetic Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Isoflurane
  • Etomidate
  • Remifentanil
  • Sevoflurane
  • Propofol
  • Other
Applications
  • Intravenous Anesthetics
  • Inhalational Anesthetics
Companies covered
  • Aspen Pharma
  • Hikma Pharmaceuticals
  • Maruishi
  • Piramal
  • AbbVie
  • Baxter Healthcare
  • B.Braun
  • Fresenius-Kabi
  • Hengrui
  • Nhwa
  • Xi'an Libang
  • Yichang Humanwell

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global General Anaesthetic Medication Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global General Anaesthetic Medication Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 General Anaesthetic Medication Market Dynamics
  1. 2.1 General Anaesthetic Medication Industry Trends
  2. 2.2 General Anaesthetic Medication Industry Drivers
  3. 2.3 General Anaesthetic Medication Industry Opportunities and Challenges
  4. 2.4 General Anaesthetic Medication Industry Restraints
3 General Anaesthetic Medication Market by Company
  1. 3.1 Global General Anaesthetic Medication Company Revenue Ranking in 2025
  2. 3.2 Global General Anaesthetic Medication Revenue by Company (2021-2026)
  3. 3.3 Global General Anaesthetic Medication Company Ranking (2024-2026)
  4. 3.4 Global General Anaesthetic Medication Company Manufacturing Base and Headquarters
  5. 3.5 Global General Anaesthetic Medication Company Product Type and Application
  6. 3.6 Global General Anaesthetic Medication Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global General Anaesthetic Medication Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 General Anaesthetic Medication Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 General Anaesthetic Medication Market by Type
  1. 4.1 General Anaesthetic Medication Type Introduction
  2. 4.1.1 Isoflurane
  3. 4.1.2 Etomidate
  4. 4.1.3 Remifentanil
  5. 4.1.4 Sevoflurane
  6. 4.1.5 Propofol
  7. 4.1.6 Other
  8. 4.2 Global General Anaesthetic Medication Sales Value by Type
  9. 4.2.1 Global General Anaesthetic Medication Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global General Anaesthetic Medication Sales Value by Type (2021-2032)
  11. 4.2.3 Global General Anaesthetic Medication Sales Value Share by Type (2021-2032)
5 General Anaesthetic Medication Market by Application
  1. 5.1 General Anaesthetic Medication Application Introduction
  2. 5.1.1 Intravenous Anesthetics
  3. 5.1.2 Inhalational Anesthetics
  4. 5.2 Global General Anaesthetic Medication Sales Value by Application
  5. 5.2.1 Global General Anaesthetic Medication Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global General Anaesthetic Medication Sales Value by Application (2021-2032)
  7. 5.2.3 Global General Anaesthetic Medication Sales Value Share by Application (2021-2032)
6 General Anaesthetic Medication Regional Value Analysis
  1. 6.1 Global General Anaesthetic Medication Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global General Anaesthetic Medication Sales Value by Region (2021-2032)
  3. 6.2.1 Global General Anaesthetic Medication Sales Value by Region: 2021-2026
  4. 6.2.2 Global General Anaesthetic Medication Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America General Anaesthetic Medication Sales Value (2021-2032)
  7. 6.3.2 North America General Anaesthetic Medication Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe General Anaesthetic Medication Sales Value (2021-2032)
  10. 6.4.2 Europe General Anaesthetic Medication Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific General Anaesthetic Medication Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific General Anaesthetic Medication Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America General Anaesthetic Medication Sales Value (2021-2032)
  16. 6.6.2 South America General Anaesthetic Medication Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa General Anaesthetic Medication Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa General Anaesthetic Medication Sales Value Share by Country, 2025 VS 2032
7 General Anaesthetic Medication Country-level Value Analysis
  1. 7.1 Global General Anaesthetic Medication Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global General Anaesthetic Medication Sales Value by Country (2021-2032)
  3. 7.2.1 Global General Anaesthetic Medication Sales Value by Country (2021-2026)
  4. 7.2.2 Global General Anaesthetic Medication Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA General Anaesthetic Medication Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada General Anaesthetic Medication Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico General Anaesthetic Medication Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany General Anaesthetic Medication Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France General Anaesthetic Medication Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. General Anaesthetic Medication Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy General Anaesthetic Medication Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain General Anaesthetic Medication Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia General Anaesthetic Medication Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands General Anaesthetic Medication Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries General Anaesthetic Medication Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China General Anaesthetic Medication Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan General Anaesthetic Medication Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea General Anaesthetic Medication Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India General Anaesthetic Medication Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia General Anaesthetic Medication Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia General Anaesthetic Medication Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil General Anaesthetic Medication Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina General Anaesthetic Medication Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile General Anaesthetic Medication Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia General Anaesthetic Medication Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru General Anaesthetic Medication Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia General Anaesthetic Medication Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel General Anaesthetic Medication Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE General Anaesthetic Medication Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey General Anaesthetic Medication Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran General Anaesthetic Medication Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt General Anaesthetic Medication Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt General Anaesthetic Medication Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt General Anaesthetic Medication Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Aspen Pharma
  2. 8.1.1 Aspen Pharma Company Information
  3. 8.1.2 Aspen Pharma Business Overview
  4. 8.1.3 Aspen Pharma General Anaesthetic Medication Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Aspen Pharma General Anaesthetic Medication Product Portfolio
  6. 8.1.5 Aspen Pharma Recent Developments
  7. 8.2 Hikma Pharmaceuticals
  8. 8.2.1 Hikma Pharmaceuticals Company Information
  9. 8.2.2 Hikma Pharmaceuticals Business Overview
  10. 8.2.3 Hikma Pharmaceuticals General Anaesthetic Medication Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Hikma Pharmaceuticals General Anaesthetic Medication Product Portfolio
  12. 8.2.5 Hikma Pharmaceuticals Recent Developments
  13. 8.3 Maruishi
  14. 8.3.1 Maruishi Company Information
  15. 8.3.2 Maruishi Business Overview
  16. 8.3.3 Maruishi General Anaesthetic Medication Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Maruishi General Anaesthetic Medication Product Portfolio
  18. 8.3.5 Maruishi Recent Developments
  19. 8.4 Piramal
  20. 8.4.1 Piramal Company Information
  21. 8.4.2 Piramal Business Overview
  22. 8.4.3 Piramal General Anaesthetic Medication Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Piramal General Anaesthetic Medication Product Portfolio
  24. 8.4.5 Piramal Recent Developments
  25. 8.5 AbbVie
  26. 8.5.1 AbbVie Company Information
  27. 8.5.2 AbbVie Business Overview
  28. 8.5.3 AbbVie General Anaesthetic Medication Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AbbVie General Anaesthetic Medication Product Portfolio
  30. 8.5.5 AbbVie Recent Developments
  31. 8.6 Baxter Healthcare
  32. 8.6.1 Baxter Healthcare Company Information
  33. 8.6.2 Baxter Healthcare Business Overview
  34. 8.6.3 Baxter Healthcare General Anaesthetic Medication Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Baxter Healthcare General Anaesthetic Medication Product Portfolio
  36. 8.6.5 Baxter Healthcare Recent Developments
  37. 8.7 B.Braun
  38. 8.7.1 B.Braun Company Information
  39. 8.7.2 B.Braun Business Overview
  40. 8.7.3 B.Braun General Anaesthetic Medication Revenue and Gross Margin (2021-2026)
  41. 8.7.4 B.Braun General Anaesthetic Medication Product Portfolio
  42. 8.7.5 B.Braun Recent Developments
  43. 8.8 Fresenius-Kabi
  44. 8.8.1 Fresenius-Kabi Company Information
  45. 8.8.2 Fresenius-Kabi Business Overview
  46. 8.8.3 Fresenius-Kabi General Anaesthetic Medication Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Fresenius-Kabi General Anaesthetic Medication Product Portfolio
  48. 8.8.5 Fresenius-Kabi Recent Developments
  49. 8.9 Hengrui
  50. 8.9.1 Hengrui Company Information
  51. 8.9.2 Hengrui Business Overview
  52. 8.9.3 Hengrui General Anaesthetic Medication Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Hengrui General Anaesthetic Medication Product Portfolio
  54. 8.9.5 Hengrui Recent Developments
  55. 8.10 Nhwa
  56. 8.10.1 Nhwa Company Information
  57. 8.10.2 Nhwa Business Overview
  58. 8.10.3 Nhwa General Anaesthetic Medication Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Nhwa General Anaesthetic Medication Product Portfolio
  60. 8.10.5 Nhwa Recent Developments
  61. 8.11 Xi'an Libang
  62. 8.11.1 Xi'an Libang Company Information
  63. 8.11.2 Xi'an Libang Business Overview
  64. 8.11.3 Xi'an Libang General Anaesthetic Medication Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Xi'an Libang General Anaesthetic Medication Product Portfolio
  66. 8.11.5 Xi'an Libang Recent Developments
  67. 8.12 Yichang Humanwell
  68. 8.12.1 Yichang Humanwell Company Information
  69. 8.12.2 Yichang Humanwell Business Overview
  70. 8.12.3 Yichang Humanwell General Anaesthetic Medication Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Yichang Humanwell General Anaesthetic Medication Product Portfolio
  72. 8.12.5 Yichang Humanwell Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst